HRP20230455T1 - Antitumorski spojevi - Google Patents
Antitumorski spojevi Download PDFInfo
- Publication number
- HRP20230455T1 HRP20230455T1 HRP20230455TT HRP20230455T HRP20230455T1 HR P20230455 T1 HRP20230455 T1 HR P20230455T1 HR P20230455T T HRP20230455T T HR P20230455TT HR P20230455 T HRP20230455 T HR P20230455T HR P20230455 T1 HRP20230455 T1 HR P20230455T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- cancer
- alkyl
- butyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 22
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 9
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (17)
1. Spoj sa formulom IC, ili njegova farmaceutski prihvatljiva sol ili ester:
[image]
pri čemu:
X je -NH-;
R1 je -OH ili -CN;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je odabran od -CHzOH i -CH2O-(C=O)Rc;
Ra je odabran od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila;
Rb je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
Rc je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila.
2. Spoj prema patentnom zahtjevu 1 odabran od formula ICa ili ICb, ili njegova farmaceutski prihvatljiva sol ili ester:
[image]
pri čemu:
X je -NH-;
R1 je -OH ili -CN;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je odabran od -CHzOH i -CH2OC(=O)Rc;
Ra je odabran od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
Rb je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
Rc je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila.
3. Spoj prema patentnom zahtjevu 1 ili 2, pri čemu R4 je odabran od -CHzOH i - CH2O(C=O)Rc pri čemu Rc je supstituirani ili nesupstituirani C1-C6 alkil; poželjno pri čemu je Rc odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila, i supstituiranog ili nesupstituiranog terc-butila; pri čemu je dalje poželjno Rc metil.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3 pri čemu R4 je -CHzOH.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu R1 je -OH.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu R2 je -C(=O)Ra grupa pri čemu Ra je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Ra odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila, pri čemu je poželjno R2 acetil.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu R3 je vodik ili -ORb pri čemu Rb je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Rb odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila, pri čemu poželjno R3 je vodik.
8. Spoj prema patentnom zahtjevu 7 pri čemu R3 je -ORb pri čemu Rb je supstituirani ili nesupstituirani C1-C6 alkil; pri čemu je poželjno Rb odabran od supstituiranog ili nesupstituiranog metila, supstituiranog ili nesupstituiranog etila, supstituiranog ili nesupstituiranog n-propila, supstituiranog ili nesupstituiranog izopropila, supstituiranog ili nesupstituiranog n-butila, supstituiranog ili nesupstituiranog izobutila, supstituiranog ili nesupstituiranog sek-butila i supstituiranog ili nesupstituiranog terc-butila, poželjno pri čemu R3 je metoksi.
9. Spoj prema patentnom zahtjevu 1 sa formulom:
[image]
[image]
ili njegova farmaceutski prihvatljiva sol ili ester.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je sol odabrana od hidroklorida, hidrobromida, hidrojodida, sulfata, nitrata, fosfata, acetata, trifluoroacetata, maleata, fumarata, citrata, oksalata, sukcinata, tartrata, malata, mandelata, metan sulfonata, p-toluen sulfonata, natrija, kalija, kalcija, amonija, etilendiamina, etanolamina, N,N-dialkilenetanolamina, trietanolamina i baznih aminokiselina.
11. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 10 ili njegovu farmaceutski prihvatljivu sol ili ester i farmaceutski prihvatljiv nosač.
12. Dozni oblik koji sadrži farmaceutsku kompoziciju prema patentnom zahtjevu 11.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol ili ester, ili kompozicija prema patentnom zahtjevu 11, ili dozni oblik prema patentnom zahtjevu 12, za primjenu kao lijek.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol ili ester, kompozicija prema patentnom zahtjevu 11, ili dozni oblik prema patentnom zahtjevu 12, za primjenu u liječenju raka.
15. Spoj, kompozicija ili dozni oblik za primjenu prema patentnom zahtjevu 14, pri čemu je rak odabran od raka pluća uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka debelog crijeva, kolorektalnog raka, raka dojke, raka gušterače, sarkoma, raka jajnika, raka prostate i raka želuca; pri čemu je poželjno rak odabran od raka pluća uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka dojke, raka gušterače i kolorektalnog raka.
16. Proces dobivanja spoja kako je definirano u bilo kojem od patentnih zahtjeva 1 do 10 ili njegove farmaceutski prihvatljive soli ili estera:
koji obuhvaća korak reagiranja spoja formule II sa spojem formule III da se dobije spoj formule IV:
[image]
pri čemu (gdje je dozvoljeno mogućim supstituentnim grupama):
X je -NH-;
R2 je -C(=O)Ra grupa;
R3 je vodik ili -ORb grupa;
R4 je odabran od -CHzOH i -CH2OC(=O)Rc;
Ra je odabran od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila;
Rb je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila; i
Rc je odabran od supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, i supstituiranog ili nesupstituiranog C2-C12 alkinila;
i koji po izboru obuhvaća dodatni korak zamjene cijano grupe u spoju formule IV sa hidroksi grupom da se dobije spoj formule IC, pri čemu R1 je OH.
17. Komplet koji sadrži terapijski efikasnu količinu spoja prema bilo kojem patentom zahtjevu 1 do 10 ili njegove farmaceutski prihvatljive soli ili estera i farmaceutski prihvatljiv nosač; komplet koji po izboru dalje sadrži uputstva za primjenu spoja u liječenju raka, i poželjnije raka odabranog od raka pluća, uključujući nesitnostanični rak pluća i sitnostanični rak pluća, raka debelog crijeva, raka dojke, raka gušterače, sarkoma, raka jajnika, raka prostate, kolorektalnog raka i raka želuca.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382228 | 2017-04-27 | ||
| EP17382497 | 2017-07-26 | ||
| PCT/EP2018/060868 WO2018197663A1 (en) | 2017-04-27 | 2018-04-27 | Antitumoral compounds |
| EP18720255.1A EP3615544B9 (en) | 2017-04-27 | 2018-04-27 | Antitumoral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230455T1 true HRP20230455T1 (hr) | 2023-07-21 |
Family
ID=62063080
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230455TT HRP20230455T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
| HRP20231233TT HRP20231233T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
| HRP20230433TT HRP20230433T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
| HRP20191442 HRP20191442T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
| HRP20191443 HRP20191443T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231233TT HRP20231233T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
| HRP20230433TT HRP20230433T1 (hr) | 2017-04-27 | 2018-04-27 | Antitumorski spojevi |
| HRP20191442 HRP20191442T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
| HRP20191443 HRP20191443T1 (hr) | 2017-04-27 | 2019-08-09 | Antitumorska sjedinjenja |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US11332480B2 (hr) |
| EP (5) | EP3395821B1 (hr) |
| JP (5) | JP6501947B2 (hr) |
| KR (3) | KR102492283B1 (hr) |
| CN (4) | CN114736219B (hr) |
| AU (4) | AU2018260314C1 (hr) |
| BR (1) | BR112019022282A2 (hr) |
| CA (1) | CA3061518A1 (hr) |
| CL (1) | CL2019003057A1 (hr) |
| CO (1) | CO2019011967A2 (hr) |
| CY (3) | CY1121885T1 (hr) |
| DK (5) | DK4101855T3 (hr) |
| EC (1) | ECSP19083967A (hr) |
| ES (5) | ES2944344T3 (hr) |
| FI (3) | FI4101855T3 (hr) |
| HK (2) | HK1255938B (hr) |
| HR (5) | HRP20230455T1 (hr) |
| HU (5) | HUE046109T2 (hr) |
| IL (3) | IL289963B2 (hr) |
| JO (1) | JOP20190254A1 (hr) |
| LT (5) | LT4101855T (hr) |
| MA (2) | MA44020B1 (hr) |
| MD (5) | MD3395821T2 (hr) |
| ME (2) | ME03467B (hr) |
| MX (3) | MX392829B (hr) |
| MY (1) | MY198004A (hr) |
| PH (1) | PH12019550224A1 (hr) |
| PL (5) | PL4101855T3 (hr) |
| PT (2) | PT3395821T (hr) |
| RS (5) | RS59173B1 (hr) |
| SG (2) | SG11201909841RA (hr) |
| SI (5) | SI3395820T1 (hr) |
| SM (5) | SMT202300169T1 (hr) |
| TN (2) | TN2019000211A1 (hr) |
| TW (3) | TWI807411B (hr) |
| UY (1) | UY37706A (hr) |
| WO (1) | WO2018197663A1 (hr) |
| ZA (1) | ZA201907119B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190254A1 (ar) * | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
| PH12022551216A1 (en) * | 2019-11-21 | 2023-07-17 | Pharma Mar Sa | Methods of treating small cell lung cancer with lurbinectedin formulations |
| PE20230785A1 (es) * | 2020-04-21 | 2023-05-11 | Pharma Mar Sa | Conjugados de anticuerpos de farmacos |
| TW202144369A (zh) * | 2020-04-26 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 海鞘素類衍生物及其製備方法與醫藥用途 |
| CN117295499A (zh) | 2021-05-19 | 2023-12-26 | 法马马有限公司 | 海鞘素的给药方案 |
| WO2024186263A1 (en) * | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
| WO2025077996A1 (en) | 2023-10-09 | 2025-04-17 | Pharma Mar, S.A. | Synthetic process for the manufacture of ecteinascidin compounds |
| EP4563149A1 (en) | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
Family Cites Families (220)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3205220A (en) | 1961-10-26 | 1965-09-07 | Lilly Co Eli | Leurosidine and leurocristine and their production |
| US4762949A (en) | 1979-06-20 | 1988-08-09 | University Of Illinois Foundation | Acyl and carbamimidoyl alkanediamines |
| GB2058047B (en) | 1979-07-11 | 1983-09-21 | Asahi Chemical Ind | Amides and amidines |
| FR2461995A1 (fr) | 1979-07-20 | 1981-02-06 | Lcc Cice Cie Europ Compo Elect | Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur |
| US4782135A (en) | 1980-09-12 | 1988-11-01 | Board Of Trustees, University Of Illinois | Composition of matter and process |
| US5137870A (en) | 1980-09-12 | 1992-08-11 | The Board Of Trustees Of The University Of Illinois | Didemnins and nordidemnins |
| EP0048149B1 (en) | 1980-09-12 | 1983-11-30 | University of Illinois Foundation | Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them |
| US4950649A (en) | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
| US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
| US4548814A (en) | 1980-12-18 | 1985-10-22 | The Board Of Trustees Of The University Of Illinois | Composition of matter and process |
| JPS5922518A (ja) | 1982-07-29 | 1984-02-04 | 余合住金産業株式会社 | 洋服タンス |
| IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US4855086A (en) | 1982-10-15 | 1989-08-08 | Burroughs Wellcome Co. | Novel pesticides, preparation and use |
| US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
| US4567253A (en) | 1984-02-03 | 1986-01-28 | Tony Durst | 2-Substituted derivatives of podophyllotoxin and etoposide |
| JPS61109717A (ja) | 1984-11-02 | 1986-05-28 | Teruhiko Beppu | 抗腫瘍剤 |
| AU585936B2 (en) | 1984-12-28 | 1989-06-29 | Conpharm A.B. | Pharmaceutically active podophyllotoxins |
| US4644072A (en) | 1985-04-12 | 1987-02-17 | Bristol-Myers Company | Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof |
| DE3684868D1 (de) | 1985-09-20 | 1992-05-21 | Cernitin Sa | Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung. |
| US4731377A (en) | 1986-01-31 | 1988-03-15 | Harbor Branch Oceanographic Institute, Inc. | Antitumor cyclic peroxides |
| AU589282B2 (en) | 1986-06-09 | 1989-10-05 | University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US4737510A (en) | 1986-09-30 | 1988-04-12 | The Board Of Trustees Of The University Of Illinois | Bioactive metabolites from the caribbean sponge agelas coniferin |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US4847246A (en) | 1987-09-11 | 1989-07-11 | Wilson George R | Antiviral compositions derived from fireflies and their methods of use |
| FR2623504B1 (fr) | 1987-11-25 | 1990-03-09 | Adir | Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5559145A (en) | 1988-06-01 | 1996-09-24 | Oxaco S.A. | 1,2,4-trioxane derivatives |
| ES2054011T3 (es) | 1988-09-05 | 1994-08-01 | Sankyo Co | Un proceso para la preparacion de un compuesto, "leualacina". |
| WO1990005731A1 (en) | 1988-11-24 | 1990-05-31 | University Of Queensland | Cytotoxic macromolecules |
| US5190876A (en) | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
| US5583160A (en) | 1989-02-03 | 1996-12-10 | The Biomembrane Institute | Methylsphingosine used to treat apoptosis |
| CA2007507C (en) | 1989-02-03 | 1998-05-19 | Yasuyuki Igarashi | Sphingosine and n-methyl-sphingosine as inhibitor of cell growth |
| US4948791A (en) | 1989-04-10 | 1990-08-14 | The Board Of Trustees Of The University Of Illinois | Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US20030148933A1 (en) | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US5053559A (en) | 1989-12-29 | 1991-10-01 | Oxaco S.A. | Cleavage of 1,2,4-trioxanes |
| KR910014122A (ko) | 1990-01-19 | 1991-08-31 | 디께다 가즈히꼬 | 에토포시드-2-디메틸아미노 화합물의 동결건조 제제 |
| JPH0539283A (ja) | 1991-01-31 | 1993-02-19 | Suntory Ltd | 新規物質Ｓ−５９９１７ａ及びその製造方法 |
| US5721352A (en) | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
| DE4120327A1 (de) | 1991-06-20 | 1992-12-24 | Basf Ag | Neue peptide, ihre herstellung und verwendung |
| US5336669A (en) | 1991-12-10 | 1994-08-09 | Erbamont, Inc. | Cyclophosphamide monohydrate and lactose |
| JPH05247055A (ja) | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
| GB9206244D0 (en) | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| GB9212000D0 (en) | 1992-06-05 | 1992-07-15 | Univ Madrid Complutense | New synthetic antitumoral compound |
| KR950702994A (ko) | 1992-08-12 | 1995-08-23 | 로렌스 티. 웰츠 | 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol) |
| US5756734A (en) | 1992-09-11 | 1998-05-26 | Pharmamar, S.A. | Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe |
| ES2059259B1 (es) | 1992-09-22 | 1995-10-01 | Pharma Mar S A Pharmar | Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral. |
| US5580871A (en) | 1992-11-20 | 1996-12-03 | The Dupont Merck Pharmaceutical Company | 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity |
| US6274551B1 (en) | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
| GB9302044D0 (en) | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Cytotoxic compounds i |
| GB9302046D0 (en) | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
| US5569757A (en) | 1993-03-30 | 1996-10-29 | Rinehart; Kenneth L. | 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1 |
| GB9308111D0 (en) | 1993-04-20 | 1993-06-02 | Pharma Gen S A | Active compound from a stonge |
| US5556777A (en) | 1993-09-09 | 1996-09-17 | Pharmamar, S.A. | Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp. |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
| US20040059112A1 (en) | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
| US5514708A (en) | 1994-02-18 | 1996-05-07 | Pharmamar, S.A. | Cytotoxic metabolites from Myriapora truncata |
| US5681813A (en) | 1994-04-06 | 1997-10-28 | Pharma Mar, S.A. | Thiodepsipeptide isolated from a marine actinomycete |
| ES2100124B1 (es) | 1994-08-01 | 1998-04-01 | Pharma Mar Sa | Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral. |
| US5514705A (en) | 1994-09-07 | 1996-05-07 | Pharmamar, S.A. | Epidioxymanadic acids A and B |
| US5523456A (en) | 1994-09-29 | 1996-06-04 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| GB9422947D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Immunosuppressive cyclolignan derivatives |
| GB9422946D0 (en) | 1994-11-14 | 1995-01-04 | Univ Salamanca | Antineoplastic cyclolignan derivatives |
| GB9504662D0 (en) | 1995-03-08 | 1995-04-26 | Pharma Mar Sa | Antitumour isocoumarins |
| US20010039041A1 (en) | 1995-06-07 | 2001-11-08 | Pharma Mar, S.A. | Immunosuppressive sesbanimide compositions and methods of treatment using same |
| US5661175A (en) | 1995-06-20 | 1997-08-26 | Kashman; Yoel | Hemiasterlin and geodiamolide TA |
| US5852033A (en) | 1995-06-29 | 1998-12-22 | Pharma Mar, S.A. | Methods of treatment using lamellarin-class alkaloids |
| ES2102322B1 (es) | 1995-07-13 | 1998-03-01 | Pharma Mar Sa | Procedimiento de preparacion de didemnina a. |
| US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
| EP0821068A3 (en) | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
| GB9608010D0 (en) | 1996-04-18 | 1996-06-19 | Pharma Mar Sa | Trunkamide A |
| US6156724A (en) | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| ATE245435T1 (de) | 1996-10-24 | 2003-08-15 | Univ Illinois | Totalsynthese des amino hip analogen von didemnin a |
| CA2269881A1 (en) | 1996-10-24 | 1998-04-30 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic studies toward didemnin analogues |
| GB9622427D0 (en) | 1996-10-28 | 1997-01-08 | Pharma Mar Sa | Antimalarial drugs |
| USRE38793E1 (en) | 1997-04-15 | 2005-09-06 | Rinehart Kenneth L | Spisulosine compounds |
| US6800661B1 (en) | 1997-04-15 | 2004-10-05 | Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| US6028077A (en) | 1997-04-15 | 2000-02-22 | Rinehart; Kenneth L. | Crambescidin compounds |
| US6107520A (en) | 1997-04-15 | 2000-08-22 | The Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| US6034058A (en) | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
| AUPO656597A0 (en) | 1997-05-02 | 1997-05-29 | Australian National University, The | Preparation of therapeutic compounds |
| US6030943A (en) | 1997-05-07 | 2000-02-29 | Crumb; William J. | Dehydrodidemnin B as an L-type calcium channel enhancer |
| GB9723206D0 (en) | 1997-11-03 | 1998-01-07 | Inst Biomar Sa | New cytotoxic pyridoacridine alkaloids |
| GB9727301D0 (en) | 1997-12-23 | 1998-02-25 | Inst Biomar Sa | Asmarine A and B: New cytotoxic alkaloids |
| US6420357B1 (en) | 1997-12-23 | 2002-07-16 | Instituto Biomar, S.A. | Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge |
| GB9801741D0 (en) | 1998-01-27 | 1998-03-25 | Inst Biomar Sa | New cytotoxic tris (oxazole)-containing macrolides |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| DE69936845T2 (de) | 1998-04-06 | 2008-05-08 | The Board Of Trustees Of The University Of Illinois, Urbana | Halbsynthetische ectein-ascidine |
| US6656948B2 (en) | 1998-04-29 | 2003-12-02 | Universidad Complutense De Madrid | Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system |
| JP2004506401A (ja) | 1998-05-05 | 2004-03-04 | ファーマ マー，ソシエダッド アノニマ | 付着性海生動物の培養 |
| CN100339375C (zh) * | 1998-05-11 | 2007-09-26 | 法马马有限公司 | 海鞘素743的代谢物 |
| GB9810998D0 (en) | 1998-05-21 | 1998-07-22 | Univ Madrid Complutense | Antitumour 1,5-diazaanthraquinones |
| US6124292A (en) | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| GB9821975D0 (en) | 1998-10-08 | 1998-12-02 | Pharma Mar Sa | New cytotoxic alkaloids |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| GB9918178D0 (en) | 2000-05-15 | 1999-10-06 | Pharma Mar Sa | Synthetic methods |
| GB9915069D0 (en) | 1999-06-28 | 1999-08-25 | Inst Biomar Sa | New indolocarbazole alkaloids from a marine actinomycete |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| AU780417B2 (en) | 1999-11-15 | 2005-03-17 | Pharma Mar S.A. | Aplidine treatment of cancers |
| WO2001053299A1 (en) | 2000-01-19 | 2001-07-26 | The Trustees Of Columbia University In The City Of New York | Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| RU2002124591A (ru) | 2000-02-16 | 2004-01-10 | Фарма Мар, С.А. (Es) | Окси- и амино-замещенные тетрагидрофурил-производные с противоопухолевой активностью |
| US20030187075A1 (en) | 2000-03-20 | 2003-10-02 | Junichi Tanaka Keith | Sponge antitumor compounds |
| US6509315B1 (en) | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
| ES2272462T3 (es) | 2000-04-07 | 2007-05-01 | The Trustees Of The University Of Pennsylvania | Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso. |
| ATE299146T1 (de) | 2000-04-12 | 2005-07-15 | Pharma Mar Sa | Ecteinaschidin derivate mit antikrebs wirkung |
| US7919493B2 (en) | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| GB0010799D0 (en) | 2000-05-04 | 2000-06-28 | Inst Biomar Sa | Stolonoxides |
| US7420051B2 (en) | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| GB0011927D0 (en) | 2000-05-17 | 2000-07-05 | Inst Biomar Sa | New use of citreamicins |
| CA2410409A1 (en) | 2000-06-06 | 2001-12-13 | Pharma Mar, S.A. | Antitumoral compounds |
| GB0016020D0 (en) | 2000-06-29 | 2000-08-23 | Inst Biomar Sa | New polyciclic xanthones and their use |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| ATE431349T1 (de) | 2000-07-11 | 2009-05-15 | Pharma Mar Sa | Variolinderivate als antikrebsmittel |
| JP4099388B2 (ja) | 2000-07-13 | 2008-06-11 | プロリズム，インコーポレイテッド | 被治療生物の体内にエネルギーを付与する装置 |
| GB0019117D0 (en) | 2000-08-03 | 2000-09-27 | Univ Barcelona | Derivatives of variolin B |
| CZ2003993A3 (cs) | 2000-10-12 | 2004-02-18 | Pharma Mar, S. A. | Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva |
| AU9402401A (en) | 2000-10-12 | 2002-04-22 | Pharma Mar Sa | Treatment of cancers |
| HK1054192B (en) | 2000-10-31 | 2006-09-08 | Pharma Mar, S.A. | New formula of KAHALALIDE F |
| CN100374162C (zh) | 2000-11-06 | 2008-03-12 | 法马马有限公司 | 海鞘素－743在制备用于治疗肿瘤的药剂中的应用 |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| US20040047807A1 (en) | 2001-01-24 | 2004-03-11 | Dominik Meyer | Use of neurotoxic substances in producing a medicament for treating joint pains |
| JP2004521122A (ja) | 2001-01-25 | 2004-07-15 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン類似体の非経口製剤 |
| WO2002064843A1 (en) | 2001-02-09 | 2002-08-22 | The Regents Of The University Of California | Ecteinascidin family compounds: compositions and methods |
| GB0105745D0 (en) | 2001-03-08 | 2001-04-25 | Pharma Gen S A | Immobilisation of ligands |
| GB0108234D0 (en) | 2001-04-02 | 2001-05-23 | Pharma Mar Sa | Process for producing trunkamide A compounds |
| GB0116966D0 (en) | 2001-07-11 | 2001-09-05 | Pharma Mar Sa | Anittumoral compounds |
| GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| AU2002334203C1 (en) | 2001-10-19 | 2008-10-09 | Pharma Mar, S.A. | Kahalalide compounds for use in cancer therapy |
| JP2005509650A (ja) | 2001-10-19 | 2005-04-14 | ファルマ・マール・ソシエダード・アノニマ | 癌治療における抗腫瘍化合物の改良した使用 |
| US20050054555A1 (en) | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
| PT1435991E (pt) | 2001-10-19 | 2009-01-16 | Pharma Mar Sa | Utilização de aplidina para o tratamento de cancro pancreático |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| US20040019027A1 (en) | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
| GB0217638D0 (en) | 2002-07-30 | 2002-09-11 | Pharma Mar Sa | Total synthesis of myriaporones |
| CA2494105C (en) | 2002-07-31 | 2013-04-02 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| GB0218813D0 (en) | 2002-08-13 | 2002-09-18 | Pharma Mar Sa | DNA sequences from an endosymbiont and their uses |
| GB0218816D0 (en) | 2002-08-13 | 2002-09-18 | Pharma Mar Sa | Antitumoral analogs of lamellarins |
| US20040033940A1 (en) | 2002-08-16 | 2004-02-19 | Pharma Mar, S.A. | Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP |
| GB0304367D0 (en) | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| CA2501089C (en) | 2002-10-18 | 2012-07-17 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalaide f compound |
| GB0229793D0 (en) | 2002-12-20 | 2003-01-29 | Pharma Mar Sa | The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| GB0303940D0 (en) | 2003-02-20 | 2003-03-26 | Pharma Mar Sau | Solid phase synthesis of antitumoral compounds |
| ES2347959T3 (es) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
| US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
| CN1761480B (zh) | 2003-03-12 | 2012-09-26 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
| MXPA05009742A (es) | 2003-03-12 | 2006-05-25 | Dana Farber Cancer Inst Inc | Aplidina para tratamiento de mieloma multiple. |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| GB0312407D0 (en) | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| GB0314726D0 (en) | 2003-06-24 | 2003-07-30 | Inst Biomar Sa | New cytotoxic depsipeptides |
| AU2004263287B2 (en) | 2003-07-25 | 2009-02-12 | Novartis Ag | Substituted lactams and their use as anti-cancer agents |
| GB0321066D0 (en) | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| EP1680415B1 (en) | 2003-10-09 | 2008-12-31 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
| GB0324201D0 (en) | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| DE602004016376D1 (de) | 2003-11-13 | 2008-10-16 | Pharma Mar Sau | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs |
| EP1691809A1 (en) * | 2003-11-14 | 2006-08-23 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| DE102004011809A1 (de) | 2004-03-11 | 2005-09-29 | Robert Bosch Gmbh | Magnetsensoranordnung |
| GB0408958D0 (en) | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
| WO2005118584A2 (en) | 2004-05-26 | 2005-12-15 | Axys Pharmaceuticals, Inc. | Saframycin analogs as therapeutic agents in the treatment of cancer |
| US7446196B2 (en) | 2004-06-03 | 2008-11-04 | Kosan Biosciences, Incorporated | Leptomycin compounds |
| CA2573072A1 (en) | 2004-07-09 | 2006-01-19 | Rafael Rosell Costa | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| AU2005288696A1 (en) | 2004-09-28 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
| US20090117176A1 (en) | 2004-10-26 | 2009-05-07 | Pharma Mar, S.A. Sociedad Unipersonal | Anticancer Treatments |
| RU2382647C2 (ru) | 2004-10-29 | 2010-02-27 | Фарма Мар С.А., Сосьедад Униперсональ | Композиции, содержащие эктинэсайдин и дисахарид |
| EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
| WO2006066183A2 (en) | 2004-12-16 | 2006-06-22 | Axys Pharmaceuticals, Inc. | Novel saframycin analogs as therapeutic agents |
| CN101171236A (zh) | 2005-05-03 | 2008-04-30 | 马尔药品公司 | 抗肿瘤的四氢嘧啶 |
| GB0515673D0 (en) | 2005-08-01 | 2005-09-07 | Pharma Mar Sa | Antitumoral compounds |
| WO2007014971A2 (es) | 2005-08-02 | 2007-02-08 | Pharma Mar, S.A. | Genes involucrados en la biosíntesis de tiocoralina y producción heteróloga de la misma |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| GB0523098D0 (en) | 2005-11-14 | 2005-12-21 | Pharma Mar Sa | Antitumoral compounds |
| JP2009517403A (ja) | 2005-11-25 | 2009-04-30 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー | Ｐａｒｐ−１阻害剤の使用 |
| ES2276629B1 (es) | 2005-12-15 | 2009-04-01 | Pharma Mar, S.A. | Compuestos antitumorales. |
| ES2288107B1 (es) | 2006-01-27 | 2008-11-01 | Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita | Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa. |
| PL2029155T3 (pl) | 2006-02-28 | 2016-09-30 | Ulepszony sposób leczenia szpiczaka mnogiego | |
| JP2009536956A (ja) | 2006-05-12 | 2009-10-22 | ファルマ・マール・ソシエダード・アノニマ | 抗癌治療法 |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| UA97369C2 (ru) | 2006-06-16 | 2012-02-10 | Фарма Мар, С.А. | Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе |
| WO2009050296A1 (en) | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Improved antitumoral treatments |
| AU2008313634A1 (en) | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
| NZ584695A (en) | 2007-10-19 | 2011-06-30 | Pharma Mar Sa | Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib) |
| ES2406107T3 (es) | 2007-12-14 | 2013-06-05 | Pharma Mar S.A. | Compuestos antitumorales |
| MY148651A (en) | 2007-12-20 | 2013-05-15 | Pharma Mar Sa | Antitumoral compounds |
| US20100323021A1 (en) | 2008-01-30 | 2010-12-23 | Pharma Mar, S.A. | Antitumoral treatments |
| EP2262522A1 (en) | 2008-03-07 | 2010-12-22 | Pharma Mar, S.A. | Improved antitumoral treatments |
| RU2010140888A (ru) | 2008-03-07 | 2012-04-20 | Фарма Мар, С.А. (Es) | Улучшенные противораковые терапии |
| WO2009140675A2 (en) | 2008-05-16 | 2009-11-19 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
| JP2011520846A (ja) | 2008-05-16 | 2011-07-21 | ファルマ・マール・ソシエダード・アノニマ | 多発性骨髄腫の治療 |
| BRPI0912294B8 (pt) | 2008-05-23 | 2021-05-25 | Wyeth Llc | compostos de triazina que inibem p13 quinase e mtor, e composições farmacêuticas dos mesmos |
| US20110118343A1 (en) | 2008-07-03 | 2011-05-19 | Pharma Mar, S. A. | Antitumoral Macrolides |
| BRPI0910810A2 (pt) | 2008-07-15 | 2019-09-24 | Genentech Inc | conjugados derivados de antraciclina, veículo polimérico, anticorpo, peptídeo ou proteína, veículo t-[cho]m, composições farmacêuticas, métodos de tratamento do câncer ou de distúrbios da proliferação celular, derivado de antraciclina, composto conjugado droga-anticorpo, uso, artigo de manufatura e método de produção de um composto conjugado droga-anticorpo" |
| KR20110043681A (ko) | 2008-07-17 | 2011-04-27 | 파르마 마르 에스.에이. | 항암 화합물 |
| MX2011006532A (es) | 2008-12-19 | 2011-07-13 | Pharma Mar Sa | Compuestos anticancerigenos. |
| WO2010149688A2 (en) | 2009-06-24 | 2010-12-29 | Pharma Mar, S.A. | Antitumoral compounds |
| UA112746C2 (uk) | 2010-04-27 | 2016-10-25 | Фарма Мар, С.А. | Протиракові стероїдні лактони, ненасичені в положенні 7(8) |
| CN107033164A (zh) * | 2010-05-25 | 2017-08-11 | 法马马有限公司 | 制备海鞘素化合物的合成方法 |
| CA2817420C (en) | 2010-11-12 | 2019-09-24 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
| DE102012211024B4 (de) | 2012-06-27 | 2024-10-24 | Robert Bosch Gmbh | Verfahren zum Betreiben eines Fahrzeuges |
| JP5922518B2 (ja) | 2012-07-20 | 2016-05-24 | 浜松ホトニクス株式会社 | シンチレータパネル及び放射線検出器 |
| GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
-
2017
- 2017-06-16 JO JOP/2019/0254A patent/JOP20190254A1/ar unknown
-
2018
- 2018-04-27 DK DK22187664.2T patent/DK4101855T3/da active
- 2018-04-27 MA MA44020A patent/MA44020B1/fr unknown
- 2018-04-27 SM SM20230169T patent/SMT202300169T1/it unknown
- 2018-04-27 RS RSP20191061 patent/RS59173B1/sr unknown
- 2018-04-27 EP EP18382288.1A patent/EP3395821B1/en active Active
- 2018-04-27 MD MDE20181217 patent/MD3395821T2/ro unknown
- 2018-04-27 KR KR1020197032625A patent/KR102492283B1/ko active Active
- 2018-04-27 RS RS20230332A patent/RS64174B1/sr unknown
- 2018-04-27 HR HRP20230455TT patent/HRP20230455T1/hr unknown
- 2018-04-27 PL PL22187664.2T patent/PL4101855T3/pl unknown
- 2018-04-27 CN CN202210424240.9A patent/CN114736219B/zh active Active
- 2018-04-27 SM SM20190448T patent/SMT201900448T1/it unknown
- 2018-04-27 HR HRP20231233TT patent/HRP20231233T1/hr unknown
- 2018-04-27 SI SI201830002T patent/SI3395820T1/sl unknown
- 2018-04-27 HU HUE18382288A patent/HUE046109T2/hu unknown
- 2018-04-27 MD MDE20221377T patent/MD4101855T2/ro unknown
- 2018-04-27 IL IL289963A patent/IL289963B2/en unknown
- 2018-04-27 ES ES22166571T patent/ES2944344T3/es active Active
- 2018-04-27 MX MX2021016054A patent/MX392829B/es unknown
- 2018-04-27 SI SI201830902T patent/SI3615544T1/sl unknown
- 2018-04-27 SM SM20230343T patent/SMT202300343T1/it unknown
- 2018-04-27 JP JP2018086737A patent/JP6501947B2/ja active Active
- 2018-04-27 PL PL22166571.4T patent/PL4047002T3/pl unknown
- 2018-04-27 EP EP18720255.1A patent/EP3615544B9/en active Active
- 2018-04-27 JP JP2019558467A patent/JP7186723B2/ja active Active
- 2018-04-27 BR BR112019022282A patent/BR112019022282A2/pt unknown
- 2018-04-27 MD MDE20200225T patent/MD3615544T2/ro unknown
- 2018-04-27 MA MA44021A patent/MA44021B1/fr unknown
- 2018-04-27 JP JP2018086736A patent/JP6501946B2/ja active Active
- 2018-04-27 TN TNP/2019/000211A patent/TN2019000211A1/en unknown
- 2018-04-27 HU HUE18720255A patent/HUE062157T2/hu unknown
- 2018-04-27 SI SI201830966T patent/SI4101855T1/sl unknown
- 2018-04-27 KR KR1020217032517A patent/KR102491180B1/ko active Active
- 2018-04-27 LT LTEP22187664.2T patent/LT4101855T/lt unknown
- 2018-04-27 UY UY0001037706A patent/UY37706A/es active IP Right Grant
- 2018-04-27 LT LTEPPCT/EP2018/060868T patent/LT3615544T/lt unknown
- 2018-04-27 HR HRP20230433TT patent/HRP20230433T1/hr unknown
- 2018-04-27 SM SM20230160T patent/SMT202300160T1/it unknown
- 2018-04-27 TW TW110133271A patent/TWI807411B/zh active
- 2018-04-27 FI FIEP22187664.2T patent/FI4101855T3/fi active
- 2018-04-27 CN CN201880027781.XA patent/CN110621678B/zh active Active
- 2018-04-27 PT PT18382288T patent/PT3395821T/pt unknown
- 2018-04-27 MY MYPI2019006255A patent/MY198004A/en unknown
- 2018-04-27 ME MEP-2019-227A patent/ME03467B/me unknown
- 2018-04-27 IL IL270153A patent/IL270153B2/en unknown
- 2018-04-27 SI SI201830901T patent/SI4047002T1/sl unknown
- 2018-04-27 TW TW112129621A patent/TWI875118B/zh active
- 2018-04-27 RS RS20230364A patent/RS64200B1/sr unknown
- 2018-04-27 HU HUE22187664A patent/HUE063736T2/hu unknown
- 2018-04-27 HU HUE18382287A patent/HUE045641T2/hu unknown
- 2018-04-27 US US16/608,617 patent/US11332480B2/en active Active
- 2018-04-27 PL PL18720255.1T patent/PL3615544T3/pl unknown
- 2018-04-27 LT LTEP18382288.1T patent/LT3395821T/lt unknown
- 2018-04-27 DK DK22166571.4T patent/DK4047002T3/da active
- 2018-04-27 SI SI201830003T patent/SI3395821T1/sl unknown
- 2018-04-27 RS RSP20191062 patent/RS59174B1/sr unknown
- 2018-04-27 DK DK18382288.1T patent/DK3395821T3/da active
- 2018-04-27 ES ES18720255T patent/ES2944579T3/es active Active
- 2018-04-27 ES ES18382288T patent/ES2741901T3/es active Active
- 2018-04-27 EP EP18382287.3A patent/EP3395820B1/en active Active
- 2018-04-27 MD MDE20181216 patent/MD3395820T2/ro unknown
- 2018-04-27 PT PT18382287T patent/PT3395820T/pt unknown
- 2018-04-27 MD MDE20220945T patent/MD4047002T2/ro unknown
- 2018-04-27 ES ES22187664T patent/ES2960063T3/es active Active
- 2018-04-27 TN TNP/2019/000210A patent/TN2019000210A1/en unknown
- 2018-04-27 MX MX2019012812A patent/MX392601B/es unknown
- 2018-04-27 SG SG11201909841R patent/SG11201909841RA/en unknown
- 2018-04-27 FI FIEP18720255.1T patent/FI3615544T3/fi active
- 2018-04-27 PL PL18382288T patent/PL3395821T3/pl unknown
- 2018-04-27 CA CA3061518A patent/CA3061518A1/en active Pending
- 2018-04-27 TW TW107114533A patent/TWI742273B/zh active
- 2018-04-27 AU AU2018260314A patent/AU2018260314C1/en active Active
- 2018-04-27 LT LTEP18382287.3T patent/LT3395820T/lt unknown
- 2018-04-27 US US15/964,381 patent/US10538535B2/en active Active
- 2018-04-27 FI FIEP22166571.4T patent/FI4047002T3/fi active
- 2018-04-27 PL PL18382287T patent/PL3395820T3/pl unknown
- 2018-04-27 EP EP22166571.4A patent/EP4047002B1/en active Active
- 2018-04-27 DK DK18382287.3T patent/DK3395820T3/da active
- 2018-04-27 DK DK18720255.1T patent/DK3615544T3/da active
- 2018-04-27 RS RS20230905A patent/RS64686B1/sr unknown
- 2018-04-27 WO PCT/EP2018/060868 patent/WO2018197663A1/en active Application Filing
- 2018-04-27 SM SM20190447T patent/SMT201900447T1/it unknown
- 2018-04-27 KR KR1020227026211A patent/KR102510975B1/ko active Active
- 2018-04-27 ES ES18382287T patent/ES2740073T3/es active Active
- 2018-04-27 CN CN202210424238.1A patent/CN114751920B/zh active Active
- 2018-04-27 IL IL295044A patent/IL295044B2/en unknown
- 2018-04-27 HU HUE22166571A patent/HUE062032T2/hu unknown
- 2018-04-27 SG SG10201913300YA patent/SG10201913300YA/en unknown
- 2018-04-27 CN CN202410023357.5A patent/CN117865987A/zh active Pending
- 2018-04-27 LT LTEP22166571.4T patent/LT4047002T/lt unknown
- 2018-04-27 ME MEP-2019-228A patent/ME03466B/me unknown
- 2018-04-27 EP EP22187664.2A patent/EP4101855B9/en active Active
- 2018-11-23 HK HK18115007.9A patent/HK1255938B/en unknown
- 2018-11-23 HK HK18115010.4A patent/HK1255941B/en unknown
-
2019
- 2019-08-09 HR HRP20191442 patent/HRP20191442T1/hr unknown
- 2019-08-09 HR HRP20191443 patent/HRP20191443T1/hr unknown
- 2019-08-13 CY CY20191100873T patent/CY1121885T1/el unknown
- 2019-08-13 CY CY20191100872T patent/CY1121884T1/el unknown
- 2019-10-24 CL CL2019003057A patent/CL2019003057A1/es unknown
- 2019-10-25 PH PH12019550224A patent/PH12019550224A1/en unknown
- 2019-10-25 CO CONC2019/0011967A patent/CO2019011967A2/es unknown
- 2019-10-25 MX MX2021016058A patent/MX2021016058A/es unknown
- 2019-10-28 ZA ZA2019/07119A patent/ZA201907119B/en unknown
- 2019-11-26 EC ECSENADI201983967A patent/ECSP19083967A/es unknown
-
2021
- 2021-04-02 US US17/221,445 patent/US11339180B2/en active Active
-
2022
- 2022-01-14 AU AU2022200250A patent/AU2022200250C1/en active Active
- 2022-01-14 AU AU2022200249A patent/AU2022200249C1/en active Active
- 2022-03-09 AU AU2022201657A patent/AU2022201657A1/en not_active Abandoned
- 2022-04-05 US US17/714,114 patent/US11713325B2/en active Active
- 2022-07-04 JP JP2022107785A patent/JP7422812B2/ja active Active
-
2023
- 2023-01-24 JP JP2023008821A patent/JP7490835B2/ja active Active
- 2023-06-15 CY CY20231100283T patent/CY1126061T1/el unknown
- 2023-06-22 US US18/213,082 patent/US20240166666A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230455T1 (hr) | Antitumorski spojevi | |
| HRP20150592T4 (hr) | Organoborni esterski spojevi i njihove farmaceutske kompozicije | |
| DE69809959T2 (de) | Neue taxanderivate | |
| EP3532069A1 (en) | Antiviral aryl-amide phosphodiamide compounds | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| Damen et al. | Paclitaxel esters of malic acid as prodrugs with improved water solubility | |
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| AU2016229147B2 (en) | Aza-pyridone compounds and uses thereof | |
| KR20060126716A (ko) | 항증식제로서의 피리도- 및 피리미도피리미딘 유도체 | |
| HRP20120351T1 (hr) | Macrociklički derivati kinazolina kao antiproliferativna sredstva | |
| EP2088141A3 (en) | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | |
| JP2018188431A5 (hr) | ||
| RS54717B1 (en) | PROSTAGLANDIN NITRO OXIDERIVES | |
| ES2899694T3 (es) | Compuestos novedosos, su síntesis y sus usos | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| HRP20160641T1 (hr) | Fuzionirani triciklički spojevi kao inhibitori raf kinaze | |
| RU2012140021A (ru) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ | |
| CN102482318A (zh) | 异噁唑烷衍生物 | |
| CN111072682A (zh) | 白屈菜碱呋咱类一氧化氮供体衍生物及其制备方法和用途 | |
| Jiang et al. | Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity | |
| CN104447782B (zh) | 溴代去甲斑蝥素单酸苄酯及其合成方法和应用 | |
| ES2995012T3 (en) | Heterocyclo alkyl compounds used as ccr2/ccr5 antagonists | |
| CN103193669B (zh) | nNOS-Capon解偶联化合物及其制备方法和应用 | |
| CN104080777A (zh) | 用作mogat-2抑制剂的新型吗啉基衍生物 | |
| CN104387392B (zh) | 制备托法替布的方法 |